Insider Selling: Palvella Therapeutics (NASDAQ:PVLA) COO Sells 4,302 Shares of Stock

Palvella Therapeutics, Inc. (NASDAQ:PVLA) COO Kathleen Goin sold 4,302 shares of the stock in a transaction that occurred on Wednesday, November 19th. The stock was sold at an average price of $86.23, for a total transaction of $370,961.46. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website.

Palvella Therapeutics Stock Performance

Shares of Palvella Therapeutics stock traded up $2.55 during midday trading on Friday, hitting $94.09. 232,882 shares of the company traded hands, compared to its average volume of 122,671. The firm’s fifty day moving average price is $71.26 and its 200-day moving average price is $46.44. The stock has a market cap of $1.11 billion, a price-to-earnings ratio of -35.78 and a beta of -0.05. Palvella Therapeutics, Inc. has a 12 month low of $11.17 and a 12 month high of $101.94.

Palvella Therapeutics (NASDAQ:PVLA) last issued its quarterly earnings data on Monday, November 10th. The company reported ($1.03) EPS for the quarter, missing the consensus estimate of ($0.85) by ($0.18). Equities research analysts forecast that Palvella Therapeutics, Inc. will post -3.69 earnings per share for the current year.

Institutional Investors Weigh In On Palvella Therapeutics

Several institutional investors and hedge funds have recently made changes to their positions in PVLA. Archer Investment Corp bought a new position in shares of Palvella Therapeutics during the third quarter worth about $28,000. Russell Investments Group Ltd. bought a new position in Palvella Therapeutics during the 3rd quarter worth approximately $36,000. Police & Firemen s Retirement System of New Jersey bought a new position in Palvella Therapeutics during the 2nd quarter worth approximately $37,000. JPMorgan Chase & Co. lifted its position in shares of Palvella Therapeutics by 108,066.7% in the 2nd quarter. JPMorgan Chase & Co. now owns 3,245 shares of the company’s stock worth $73,000 after purchasing an additional 3,242 shares during the period. Finally, MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. bought a new stake in shares of Palvella Therapeutics in the 2nd quarter valued at $85,000. Institutional investors and hedge funds own 40.11% of the company’s stock.

Analyst Ratings Changes

Several research firms recently weighed in on PVLA. HC Wainwright raised their price objective on Palvella Therapeutics from $95.00 to $190.00 and gave the company a “buy” rating in a report on Thursday, November 6th. Chardan Capital reiterated a “buy” rating and issued a $110.00 target price on shares of Palvella Therapeutics in a research report on Thursday, November 13th. Weiss Ratings reissued a “sell (d-)” rating on shares of Palvella Therapeutics in a research note on Wednesday, October 8th. Oppenheimer reaffirmed an “outperform” rating on shares of Palvella Therapeutics in a research note on Tuesday, November 11th. Finally, Canaccord Genuity Group lifted their target price on shares of Palvella Therapeutics from $90.00 to $148.00 and gave the stock a “buy” rating in a research report on Thursday, November 13th. Two analysts have rated the stock with a Strong Buy rating, ten have given a Buy rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat.com, the company presently has a consensus rating of “Buy” and a consensus price target of $111.92.

Palvella Therapeutics Company Profile

Palvella Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapies to treat patients suffering from serious, rare genetic skin diseases. Palvella Therapeutics Inc, formerly known as Pieris Pharmaceuticals Inc, is based in WAYNE, Pa.